Andrea Hayes
Nashville, TNNPI 1992744676
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $175,262 of the $201,120 with a category attached, or 87.1%. 36 manufacturers reported payments, led by Novo Nordisk at 49.5% of the total. Reporting peaked in 2019 at $97,070 and has fallen 99.7% since, to $243 in 2023.
Across 942 payments — averaging $213.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$100K
- Sanofi-aventis U.S. LLC$18K
- Esperion Therapeutics, Inc.$17K
- Tandem Diabetes Care, Inc.$16K
- Merck$14K
- Insulet Corporation$11K
- plus $27K from 30 others
What the payments were for
- Consulting fees$8500%
- Speaking & faculty fees$175,26287%
- Travel & lodging$8,1584%
- Food & beverage$16,8248%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 154 | $99,501 |
| Sanofi-aventis U.S. LLC | 75 | $18,013 |
| Esperion Therapeutics, Inc. | 29 | $16,505 |
| Tandem Diabetes Care, Inc. | 46 | $15,919 |
| Merck | 44 | $13,527 |
| Insulet Corporation | 46 | $10,632 |
| Lilly USA, LLC | 82 | $6,789 |
| Valeritas, Inc. | 20 | $6,752 |
| Mannkind Corporation | 139 | $2,974 |
| Senseonics, Incorporated | 7 | $2,900 |
| Medtronic(2 entities) | 40 | $1,966 |
| Abbott | 57 | $975 |
| Boehringer Ingelheim | 43 | $961 |
| Amgen | 46 | $961 |
| AstraZeneca(2 entities) | 26 | $786 |
| Dexcom, Inc. | 21 | $381 |
| Bayer | 2 | $244 |
| AbbVie | 15 | $220 |
| Johnson & Johnson | 7 | $146 |
| Corcept Therapeutics | 1 | $140 |
| Lifescan, Inc. | 6 | $121 |
| Regeneron Healthcare Solutions, Inc. | 7 | $106 |
| Amarin Pharma, Inc. | 1 | $106 |
| Radius Health, Inc. | 6 | $83 |
| Xeris Pharmaceuticals, Inc. | 4 | $74 |
| Zealand Pharma US, Inc. | 3 | $66 |
| Companion Medical, Inc. | 2 | $51 |
| Shire North American Group Inc | 3 | $49 |
| Gilead | 1 | $42 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Pfizer | 2 | $31 |
| Aytu Biopharma, Inc. | 1 | $18 |
| Redhill Biopharma Inc. | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
| IBSA Pharma Inc. | 1 | $12 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$48,529
- RYBELSUS$33,899
- NEXLIZET$16,201
- NEXLETOL$16,201
- Tresiba$13,944
- SOLIQUA 100/33$13,831
- STEGLATRO$13,021
- t-slim insulin pump$11,500
- Omnipod$10,127
- TOUJEO$6,707
- V-GO$6,380
- t:slim X2 insulin pump$4,400
- Eversense$2,800
- AFREZZA$1,186
- Minimed 670G System$1,097
- FARXIGA$354
- Kerendia$244
- Korlym$140
- FreeStyle Libre Pro$132
- DEXCOM G7 GSS (161)$121
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 20 | $20,818 |
| SynthroidLevothyroxine Sodium | 12 | $583 |
| Rosuvastatin Calcium | 20 | $275 |
| Amlodipine Besylate | 12 | $56 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $99,501 | $20,81820 claims |
| AbbVieSynthroid | $220 | $58312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Tennesseeon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.